



**S1 Fig.** Kaplan-Meier curve for progression-free survival (PFS) according to presence or absence of acneiform eruption (A), hypertension (B), and proteinuria (C) during the treatment of bevacizumab plus erlotinib in patients with hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma.